Literature DB >> 8416309

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.

B L Kasiske1, R S Kalil, J Z Ma, M Liao, W F Keane.   

Abstract

OBJECTIVE: To assess the relative effect of different antihypertensive agents on proteinuria and renal function in patients with diabetes. DATA SOURCES: We used MEDLINE and bibliographies in recent articles to identify studies of the effects of antihypertensive agents on renal function in patients with diabetes. STUDY SELECTION: We selected 100 controlled and uncontrolled studies that provided data on renal function, proteinuria, or both, before and after treatment with an antihypertensive agent. DATA EXTRACTION: Data on blood pressure, renal function, proteinuria, patient characteristics (for example, age, sex, and type of diabetes), and study design (for example, random allocation and the use of a placebo) were extracted from selected studies. DATA SYNTHESIS: Multiple linear regression analysis indicated that angiotensin-converting enzyme (ACE) inhibitors decreased proteinuria independent of changes in blood pressure, treatment duration, and the type of diabetes or stage of nephropathy, as well as study design (P < 0.0001). Reductions in proteinuria from other antihypertensive agents could be entirely explained by changes in blood pressure. Blood pressure reduction in itself was associated with a relative increase in glomerular filtration rate (regression coefficient [+/- SE], 3.70 +/- .92 mL/min for each reduction of 10 mm Hg in mean arterial pressure; P = 0.0002); however, compared with other agents, ACE inhibitors had an additional favorable effect on glomerular filtration rate that was independent of blood pressure changes (3.41 +/- 1.71 mL/min; P = 0.05).
CONCLUSION: Angiotensin-converting enzyme inhibitors can decrease proteinuria and preserve glomerular filtration rate in patients with diabetes. These effects occur independent of changes in systemic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8416309     DOI: 10.7326/0003-4819-118-2-199301150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  71 in total

Review 1.  Recent advances: nephrology.

Authors:  C R Tomson
Journal:  BMJ       Date:  2000-01-08

Review 2.  Complications of diabetes: renal disease and promotion of self-management.

Authors:  A Melville; R Richardson; D Lister-Sharp; A McIntosh
Journal:  Qual Health Care       Date:  2000-12

Review 3.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 6.  Remission of renal disease: recounting the challenge, acquiring the goal.

Authors:  Barry M Brenner
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 7.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

Review 8.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 9.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 10.  Antihypertensive drugs and the kidney.

Authors:  Mitra K Nadim; Renee Dua; Vito M Campese
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.